Skip to main content

Hereditary Angioedema clinical trials at University of California Health

2 research studies open to eligible people

Showing trials for
  • Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

    open to eligible people ages 18 years and up

    This is a Phase 1/2, single-arm, open-label, dose-escalation and dose-expansion study of BMN 331 for the treatment of hereditary angioedema (HAE) due to C1 Esterase Inhibitor (C1-INH) protein deficiency. The study drug BMN 331is identified as AAV5 hSERPING1, an adeno-associated virus (AAV5)-based gene therapy vector that expresses wild-type human C1 Esterase Inhibitor (hC1-INH), under the control of a liver-selective promoter, and is being developed for the treatment of HAE with C1-INH deficiency. The pharmaceutical form of BMN 331 is a solution for intravenous infusion.

    at UCSD

  • STAR-0215 in Participants With Hereditary Angioedema

    open to eligible people ages 18 years and up

    The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of STAR-0215, and two other groups will get 2 doses of STAR-0215. Researchers will study the effects of STAR-0215 in participants with HAE as this is the first time that the drug has been given to participants with HAE.

    at UCSD

Our lead scientists for Hereditary Angioedema research studies include .

Last updated: